#ALS AWARENESS #LouGehrigsDisease #PARKINSONS

The United States Food and Drug Administration FDA has granted orphan designation for Herantis Pharma Plc’s (“Herantis”) CDNF for treatment of amyotrophic lateral sclerosis (ALS). Earlier this year the European Medicines Agency EMA issued a corresponding positive decision.